How to Preserve Fertility in Young Women Exposed to Chemotherapy? The Role of GnRH Agonist Cotreatment in Addition to Cryopreservation of Embrya, Oocytes, or Ovaries

CME Activity Information
Release Date:	October 03, 2007
Most Recent Review:	October 03, 2007*
Most Recent Update:	October 03, 2007
Date Credit Expires:	October 03, 2009
Time to Complete:	1 hour
Medium:	Internet Online
*Click here to learn more about our review process.

Instructions for Participation

1. Read the following information before beginning the educational activity and click the "Take this course" link at the bottom of the page
2. Study the educational activity
3. Complete the CME quiz and evaluation
4. After successful completion of the CME quiz and evaluation, you will receive the credit or participation certificate

   *The CME quiz and evaluation must be completed by October 3, 2009, in order to receive the credit or participation certificate.

1. Discuss the possibilities for preserving fertility in women exposed to chemotherapy.
2. List the possible mechanisms put forward to explain the beneficial effect of GnRH agonists in minimizing the gonadotoxic effect of chemotherapy, in particular that of alkylating agents.
3. Identify the advantages and possible risks and shortcomings of each of the proposed methods for fertility preservation in women exposed to gonadotoxic chemotherapy.
4. Discuss the possibility of combining several methods to maximize the chances of fertility preservation in these patients.
5. Explain the gender differences between male and female patients regarding the methods of fertility preservation.

All information is submitted and reviewed and found to be scientifically rigorous, based on the best available evidence, fair and balanced, and free of commercial bias. All the recommendations involving clinical medicine in this CME activity are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection and analysis.

Any potential conflicts of interests are resolved via The Oncologist's anonymous peer review process All manuscripts are reviewed by the Editorial Board with ad hoc assistance from two or more external experts in the field. All final publication decisions are made by the Editorial Board. The acceptance of a manuscript is based on its originality and importance to the field as assessed by the Editors.

Credentials: Department of Obstetrics and Gynecology, Rambam Medical Center, Technion-Faculty of Medicine, Haifa, Israel. Telephone: 972-4-8542577; Fax: 972-4-8543746; E-mail: bzeev{at}techunix.technion.ac.il or z_blumenfeld{at}rambam.health.gov.il.
Disclosures: The author has indicated no relevant commercial relationships. Also, the author has indicated that he discusses the unlabeled, investigational, or alternative use(s) GnRH-agonist [Decapeptyl] CR1 manufactured by Ferring [Germany] for fertility preservation.

• Take this course